Travere Therapeutics, Inc. TVTX
59.44
(1.18)
(1.95%)
as of 25 Sep
- Market cap
- $5.7B
- P/E
- 0.0×
Follow TVTX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.98 | 5.09 | 6.95 | 4.89 | |
P/FCF ratio |
366.95 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
91.45 | (67.62) | 56.18 | 148.96 | |
P/B ratio |
216.56 | 27.65 | 29.69 | 28.99 | |
Price to Tangible BV |
0.00 | 0.00 | 3,550.82 | 0.00 | |
EV/Sales |
9.17 | 5.18 | 6.92 | 5.02 | |
EV/EBITDA |
269.67 | 208.91 | 0.00 | 0.00 | |
EV/Operating CF |
58.51 | 70.10 | 89.92 | (37.35) | |
EV/FCF |
374.80 | (93.71) | (161.30) | (20.30) | |
Quick Ratio |
3.75 | 2.81 | 2.52 | 2.50 | |
Current Ratio |
4.05 | 3.13 | 2.74 | 2.75 | |
Net Debt/EBITDA |
13.87 | (4.05) | 0.65 | 1.40 | |
Debt/Assets |
75.41% | 56.21% | 51.51% | 57.81% | |
Debt/Equity |
24.58 | 3.16 | 2.71 | 4.23 | |
Asset Turnover |
0.87 | 0.97 | 0.82 | 0.84 | |
Operating CF/Net income |
(1.67) | 1.09 | 22.23 | 0.56 | |
Capex/Depreciation |
(4.98) | (0.88) | (1.25) | (0.98) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
35.55% | 44.89% | 44.62% | 31.48% | |
Selling, General and Administrative Expense of Revenue |
56.68% | 63.09% | 98.51% | 52.44% | |
Intangible Assets out of Total Assets |
0.16 | 0.20 | 0.19 | 0.20 | |
Share Based Compensation of Revenue |
12.85% | 12.69% | 8.84% | 6.83% | |
Graham Net Nets |
(0.03) | (0.02) | (0.02) | (0.04) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.79%) | (0.74%) | (0.76%) | (4.39%) | |
Free Cash Flow Yield |
0.27% | (1.09%) | (0.62%) | (5.06%) | |
Revenue per Share |
1.81 | 1.38 | 1.45 | 1.85 | |
Operating CF per Share |
0.62 | (0.44) | 0.68 | 0.16 | |
Capex per Share |
(0.23) | (0.24) | (0.22) | (0.17) | |
Free Cash Flow per Share |
0.40 | (0.68) | 0.46 | (0.01) | |
Cash per Share |
5.23 | 2.88 | 3.62 | 2.85 | |
Shareholders Equity per Share |
0.26 | 1.07 | 1.29 | 0.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.26 | 1.07 | 1.29 | 0.82 | |
Free Cash Flow |
37.00 | (62.54) | 41.44 | (1.11) | |
Working Capital |
463.12 | 267.24 | 277.66 | 236.04 | |
Capital Expenditures |
(21.07) | (22.18) | (19.24) | (15.42) | |
Net Current Asset Value |
(159.70) | (63.78) | (52.80) | (93.91) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.12 | 0.17 | 0.15 | 0.09 | |
Net Profit Margin |
(20.52%) | (29.17%) | 2.10% | 15.59% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
59.68 | 60.84 | 53.63 | 54.08 | |
Average Payables |
13.31 | 14.14 | 24.17 | 20.71 | |
Average Inventory |
5.96 | 5.14 | 6.04 | 5.95 | |
Average Assets |
677.33 | 551.99 | 599.66 | 521.50 | |
Average Common Equity |
28.63 | 65.78 | 86.95 | 21.56 |
Columns are period end dates